Another Reason Biopharma Insider Trading Is A Dumb Idea
This article was originally published in Scrip
Executive Summary
Two tax and estate planning lawyers and an accountant, plus two other men, have learned the hard way crime doesn't pay, especially when trying to trade on inside information involving biopharmaceutical firms – a sector the Securities and Exchange Commission (SEC) has been keeping a particularly close eye on in recent years.